Patient dosing is underway in a phase 2b/3 trial investigating ALY688 ophthalmic solution for the treatment of dry eye disease, according to a press release from Allysta Pharmaceuticals.
Up to 900 subjects who have moderate to severe signs and symptoms of dry eye will be enrolled in the randomized, double-masked, vehicle-controlled, multicenter OASIS-1 trial. Two concentrations of ALY688 are under evaluation for efficacy and safety vs. vehicle administered twice daily for 12 weeks.
ALY688 ophthalmic solution is a novel formulation containing ALY688 peptide that targets chronic inflammation and